869094-19-9
Chemical Structure
AtuFECT01
- CAS No.: 869094-19-9
- Formula:C43H90Cl3N7O2
- Molecular Weight:843.58
IUPAC Name: (S)-2-amino-N-((S)-2-amino-3-(hexadecyl((Z)-octadec-9-en-1-yl)amino)-3-oxopropyl)-5-guanidinopentanamide hydrochloride
InChIKey: UPGACERKWPBHRP-BTYIVCGTSA-N
SMILES: N=C(N)NCCC[C@H](N)C(NC[C@H](N)C(N(CCCCCCCCCCCCCCCC)CCCCCCCC/C=C\CCCCCCCC)=O)=O.Cl.Cl.Cl
Biological Activity: AtuFECT01 is a cationic lipid component. AtuFECT01 is used to construct AtuPLEX/Atu027 Lipid nanoparticles. AtuFECT01 improves cellular uptake and endosomal escape of siRNA in AtuFECT01-based lipoplexes. Formulation of AtuFECT01 with Tie2 siRNA into lipoplexes reduces Tie2 expression in mouse lung[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AtuFECT01 | AtuFECT01 is a cationic lipid component. AtuFECT01 is used to construct AtuPLEX/Atu027 Lipid nanoparticles. AtuFECT01 improves cellular uptake and endosomal escape of siRNA in AtuFECT01-based lipoplexes. Formulation of AtuFECT01 with Tie2 siRNA into lipoplexes reduces Tie2 expression in mouse lung. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Miller AD, et al. Delivery of RNAi therapeutics: work in progress. Expert review of medical devices. 2013 Nov;10(6):781-811. [Content Brief]
- [2]. Santel A, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene therapy. 2006 Aug;13(16):1222-34.
- [3]. Fehring V, et al. Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Molecular therapy : the journal of the American Society of Gene Therapy. 2014 Apr;22(4):811-20.
- [4]. Hattori Y, et al. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. Journal of drug targeting. 2019 Feb;27(2):217-227. [Content Brief]
